Aggregator
小児における近視の進行を遅らせるための介入方法
妊娠糖尿病になることを防ぐために、妊娠中にミオイノシトールを栄養補助食品として摂取すること
Cochrane seeks Finance Assistant
Specifications: Permanent – Full Time
Salary: 28,000 per annum
Location: UK – Remote/Flexible
Directorate: Finance and Corporate Services Directorate
Closing date: 26 Feb 2023
Cochrane is an international charity. For 30 years we have responded to the challenge of making vast amounts of research evidence useful for informing decisions about health. We do this by synthesising research findings and our work has been recognised as the international gold standard for high quality, trusted information.
Cochrane's strength is in its collaborative, global community. We have 110,000+ members and supporters from more than 220 countries. Though we are spread out across the globe, our shared passion for health evidence unites us. Our Central Executive Team supports this work and is divided into five directorates: Evidence Production and Methods, Publishing and Technology, Development, and Finance and Corporate Services.
Your role will play an important part in ensuring that day-to-day finance is run smoothly. You will be someone who can learn new systems and processes quickly, is numerate and accurate in their work and has good attention to detail. This role sits within the Finance and Corporate Services Directorate. You will be one of four employees that make up the finance team. You will report to the Financial Accountant.
This is a work from home position, but you will have to attend meetings in London occasionally
Don’t have every single qualification? We know that some people are less likely to apply for a job unless they are a perfect match. At Cochrane, we’re not looking for “perfect matches.” We’re looking to welcome people to our diverse, inclusive, and passionate workplace. So, if you’re excited about this role but don’t have every single qualification, we encourage you to apply anyway. Whether it’s this role or another one, you may be just the right candidate.
Our organization is built on four core values: Collaboration: Underpins everting we do, locally and globally. Relevant: The right evidence at the right time in the right format. Integrity: Independent and transparent. Quality: Reviewing and improving what we do, maintaining rigour and trust.
You can expect:
- An opportunity to truly impact health globally
- A flexible work environment
- A comprehensive onboarding experiences
- An environment where people feel welcome, heard, and included, regardless of their differences
Cochrane welcomes applications from a wide range of perspectives, experiences, locations and backgrounds; diversity, equity and inclusion are key to our values.
How to apply
- For further information on the role and how to apply, please click here.
- The deadline to receive your application is 26th Feb 2023.
- The supporting statement should indicate why you are applying for the post, and how far you meet the requirements, using specific examples.
- Read our Recruitment Privacy Statement
Podcast: Music for insomnia in adults
Podcast: Are corticosteroids (anti-inflammatory medicines) given orally or by injection an effective treatment for people with COVID-19?
Cochrane's 2023 International Women’s Day Event - Recording available
In recognition of 2023 International Women's Day (IWD), Cochrane hosted a virtual event. The event featured a panel of accomplished women from diverse backgrounds discussing the IWD 2023 theme of #EmbraceEquity.
The panelists will shared their experiences and insights on topics such as gender equity in clinical trials, the impact of gender on health outcomes, and strategies for promoting equity in healthcare and in evidence synthesis.
Tiffany Duque, Cochrane US Senior Officer and Panelist says, "The 2023 IWD event was run by our talented Cochrane US Mentees. This is the second cohort through the Cochrane Mentoree program. They come from 12 different countries and range from students to early career professionals; all with a shining future in Cochrane."
"We were excited to bring together this group of dynamic women to discuss issues of equity in healthcare," says Paola Andrencci, Cochrane US Mentor Program coordinator and lead on this event. "Their diverse perspectives and experiences will help us identify the barriers to equity and work towards solutions that benefit all patients. We thank everyone from the Cochrane community and beyond that joined us for this event!"
We welcome everyone to watch a recording of the event:
Several other videos were recorded for IWD and shared on social media:
Rehab Emad Ashmawy (Cochrane US mentee, Egypt) interviews Senator Professor Randa Mostafa. Many thanks to Mohmed Gamal for his efforts and time in capturing and editing this video.
Dr. Manar Ahmed Kamal introduces herself and answers a few questions.
Many thanks to Yasmine Ayman, Rahma Sameh, and Rawan Osama for their time and effort in filming this video.
Dr Sara Nasser (Chief Executive Officer, Pan Arabian Society of Gynecologic Oncology Research) shares her work and speaks about the importance of courage.
Related resources:
- VIDEO: 2022 International Women's Day Panel on gender bias in health science and evidence synthesis
- VIDEO: 2021 International Women's Day Panel on diversity in health evidence synthesis
- Celebrating Anne Anderson and Cochrane diversity with new designs: an interview with artist Heather Tubwon
- Cochrane Indonesia’s Director reflects on her continued contributions to maternal and perinatal health and the work of Cochrane
リハビリテーションを必要とする人々に対する在宅リハビリテーションサービスの提供に影響を与える要因:質的エビデンス統合
神経難病で長期肺感染症の小児への抗菌薬投与
Most widely followed COPD guideline updates their recommendations with Cochrane Airways reviews
The recently updated GOLD report includes evidence from 7 Cochrane Airways systematic reviews, helping to align it with the latest and best available evidence.
Chronic obstructive lung disease (COPD) is usually caused by smoking or other airway irritants. COPD damages the lungs and causes airways to narrow which makes it difficult to breathe.
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) works with healthcare professionals and public health officials worldwide to raise awareness of COPD and improve the prevention and treatment of this lung disease. The GOLD strategy document for diagnosing, managing, and preventing COPD and the corresponding pocket guide is developed for healthcare professionals based on the best scientific information available. This global evidence-based document is used as a tool to implement effective management programs based on local healthcare systems around the world.
"The GOLD Report is the most widely accepted and followed COPD guideline," explains Emma Jackson, Managing Editor of Cochrane Airways. "We were pleased to see that 7 Cochrane Airways systematic reviews were added to the GOLD Report 2023 recommendations for the first time; over 35 Cochrane Reviews are already referenced in the GOLD Report."
"Cochrane is a not-for-profit organization with collaborators from more than 190 countries working together to produce credible, accessible health information that is free from commercial sponsorship and other conflicts of interest,” says Rebecca Fortescue, Co-ordinating Editor for Cochrane Airways Editor. “Cochrane Reviews are known as the ‘gold standard’ when it comes to health evidence synthesis. We are delighted to see that 7 Cochrane Airway reviews were added in the 2023 GOLD Report to help align clinical practice with the latest and best available evidence.”
The seven reviews included in the 2023 Report for the first time are:
- Dual combination therapy versus long‐acting bronchodilators alone for chronic obstructive pulmonary disease (COPD)
- Inhaled corticosteroids for the treatment of COVID-19
- Interventions to improve adherence to pharmacological therapy for chronic obstructive pulmonary disease (COPD)
- Integrated disease management interventions for patients with chronic obstructive pulmonary disease
- Chronic non-invasive ventilation for chronic obstructive pulmonary disease
- Self-management interventions for people with chronic obstructive pulmonary disease
- Mucolytics for bronchiectasis
Lead author of the review on dual combination inhaler therapy, Yuji Oba says, “COPD is the third leading cause of death worldwide. Inhaler therapy is the mainstay treatment of COPD and the choice of inhalers is of paramount importance for patients and healthcare providers. The 2018 Cochrane review addressed which inhaler was the most efficacious and safe in the advanced form of COPD. We are proud to see the GOLD Report was updated and modified the first choice of inhaler treatment based on our Cochrane review. We are currently updating this Cochrane review and are looking forward to having our work contribute to future GOLD Reports."
Wednesday, February 8, 2023 Category: The difference we make慢性疾患を持つ小児やティーンエイジャーの教育を支援するサービスは、彼らが学校活動にもっと参加し、学習結果を向上させるのに役立つか?
Cochrane seeks Internal Communications Manager
Title: Internal Communications Manager
Specifications: Permanent – Full Time
Salary: £52,508
Location: Ideally based in the UK, Germany or Denmark. Candidates from the rest of the world will be considered; however, Cochrane’s Central Executive Team is only able to offer consultancy contracts outside these countries (1-year fixed-term contracts)
Directorate: Development
Closing date: 20 Feb 2023
Interview date: 9 March 2023
Cochrane is an international charity. For 30 years we have responded to the challenge of making vast amounts of research evidence useful for informing decisions about health. We do this by synthesising research findings and our work has been recognised as the international gold standard for high quality, trusted information.
Cochrane's strength is in its collaborative, global community. We have 110,000+ members and supporters from more than 220 countries. Though we are spread out across the globe, our shared passion for health evidence unites us. Our Central Executive Team supports this work and is divided into five directorates: Evidence Production and Methods, Publishing and Technology, Development, and Finance and Corporate Services.
This is an exciting opportunity to build a new function from the ground up, as Cochrane’s first dedicated internal communications role. The first priority for this role will be to establish effective internal communications structures and processes for Cochrane’s~100 core staff, who are distributed across multiple countries and time zones. This includes developing an intranet and regular staff communications.
Don’t have every single qualification? We know that some people are less likely to apply for a job unless they are a perfect match. At Cochrane, we’re not looking for “perfect matches.” We’re looking to welcome people to our diverse, inclusive, and passionate workplace. So, if you’re excited about this role but don’t have every single qualification, we encourage you to apply anyway. Whether it’s this role or another one, you may be just the right candidate.
Our organization is built on four core values: Collaboration: Underpins everything we do, locally and globally. Relevant: The right evidence at the right time in the right format. Integrity: Independent and transparent. Quality: Reviewing and improving what we do, maintaining rigour and trust.
You can expect:
- An opportunity to truly impact health globally
- A flexible work environment
- A comprehensive onboarding experiences
- An environment where people feel welcome, heard, and included, regardless of their differences
Cochrane welcomes applications from a wide range of perspectives, experiences, locations and backgrounds; diversity, equity and inclusion are key to our values.
How to apply
- For further information on the role and how to apply, please click here.
- The deadline to receive your application is 20 Feb 2023.
- If you are invited for interview, this will take place on 9 March 2023 via Teams.
- The supporting statement should indicate why you are applying for the post, and how far you meet the requirements, using specific examples.
- Read our Recruitment Privacy Statement
Cochrane seeks Future of Evidence Synthesis Administrative Support Officer
Title: Future of Evidence Synthesis Administrative Support Officer
Specifications: Fixed Term – 2 Years
Location: UK – Remote/Flexible
Salary: £27,071
Directorate: Evidence Production & Methods
Closing date: 20 Feb 2023
Cochrane is an international charity. For 30 years we have responded to the challenge of making vast amounts of research evidence useful for informing decisions about health. We do this by synthesising research findings and our work has been recognised as the international gold standard for high quality, trusted information.
Cochrane's strength is in its collaborative, global community. We have 110,000+ members and supporters from more than 220 countries. Though we are spread out across the globe, our shared passion for health evidence unites us. Our Central Executive Team supports this work and is divided into five directorates: Evidence Production and Methods, Publishing and Technology, Development, and Finance and Corporate Services.
The Future of Evidence Synthesis (FES) is a critical programme of work for Cochrane over the next 3-5 years. Successful delivery is essential is Cochrane to achieve the Strategy for Change objectives and become a sustainable organisation. This role provides effective and efficient administrative support for the FES programme generally and supports the pilot phase of the Thematic Group pilot specifically.
Don’t have every single qualification? We know that some people are less likely to apply for a job unless they are a perfect match. At Cochrane, we’re not looking for “perfect matches.” We’re looking to welcome people to our diverse, inclusive, and passionate workplace. So, if you’re excited about this role but don’t have every single qualification, we encourage you to apply anyway. Whether it’s this role or another one, you may be just the right candidate.
Our organization is built on four core values: Collaboration: Underpins everything we do, locally and globally. Relevant: The right evidence at the right time in the right format. Integrity: Independent and transparent. Quality: Reviewing and improving what we do, maintaining rigour and trust.
You can expect:
- An opportunity to truly impact health globally
- A flexible work environment
- A comprehensive onboarding experiences
- An environment where people feel welcome, heard, and included, regardless of their differences
Cochrane welcomes applications from a wide range of perspectives, experiences, locations and backgrounds; diversity, equity and inclusion are key to our values.
How to apply
- For further information on the role and how to apply, please click here
- The deadline to receive your application is 20 Feb 2023.
- The supporting statement should indicate why you are applying for the post, and how far you meet the requirements, using specific examples.
- Read our Recruitment Privacy Statement
ビタミンDは重度の喘息発作のリスクを低減、または喘息症状の管理を改善するか?
知的障害がある人の攻撃的行動を軽減するための行動療法と認知行動療法
Early registration now open for Cochrane London 2023
You can now register for the Cochrane Colloquium, which will take place at the Queen Elizabeth II (QEII) Centre in London from 4th to 6th September 2023, with Satellite events on 3rd September.
The Colloquium is an annual event for everyone with an interest in the use of evidence in healthcare decision making including those engaged in evidence production, co-production, dissemination, implementation and policy making, as well as those making individual healthcare decisions.
This year’s theme is ‘Forward together for trusted evidence’. It will explore the challenges for the future around the trustworthiness of healthcare data and information whilst also celebrating 30 years of producing trusted evidence.
Students, healthcare consumers, and people from low-income, lower-middle-income, and upper-middle-income economies (LMIC) are eligible for a reduced rate.
As well as now being able to register, you can submit an abstract or submit a workshop for the event.
We look forward to welcoming you to London!
Register today:- Register here
- Registration fees – reduced early bird rate ends on 01 June 2023
- Registration guidelines and policies
Local steroid injection for carpal tunnel syndrome
サラセミア患者に対する歯科および歯科矯正治療
手根管症候群に対するステロイド局所注射
Cochrane review finds that vitamin D does not reduce risk of asthma attacks
These findings are in contrast to a previous Cochrane review that indicated a reduction in asthma attacks in people taking vitamin D. However, the review found no harm in taking vitamin D and it did not examine other possible health benefits.
The review was carried out by researchers from Queen Mary University of London and the University of Edinburgh. Researcher Adrian Martineau, Clinical Professor of Respiratory Infection and Immunity at Queen Mary University of London, said: “Vitamin D deficiency has been linked to an increased risk of severe asthma attacks and our previous Cochrane review, published in 2016, found that vitamin D reduced the risk of asthma attacks. However, more studies have been published since then and when we included the extra data in our updated review, the overall results changed. We found that vitamin D supplements had no effect on risk of asthma attacks or on control of asthma symptoms compared with a placebo.”
Professor Martineau and his colleagues analysed the results of 20 randomised controlled trials – the gold-standard for medical research – including data on 1,155 children and 1,070 adults with asthma. This compares to nine trials involving a total of 1,093 people whose data contributed to the previous review. The majority of patients in the trials had mild to moderate asthma.
When they compared patients who were assigned to take a vitamin D supplement with patients who were assigned to take a placebo (dummy medication), the researchers found no statistically significant difference in the number of people who experienced an asthma attack requiring treatment with a course of steroid tablets.
The review did not find any effect of taking vitamin D on asthma control even when people were vitamin D-deficient when they joined the studies, or with different doses of the supplement, or in people of different ages.
Professor Martineau said: “In contrast to our previous Cochrane review on this topic, this updated review does not find that vitamin D offers protection against asthma attacks or improves control of asthma symptoms. However, the trials we looked at did not include many people with severe asthma or people with very low levels of vitamin D in their blood, so these are areas where more research is still needed."
Anne Williamson, the first author on the study who is also from Queen Mary University of London, commented: “We can’t be certain why this updated review has given a different result to our original study from 2016. It could be that people with asthma may be getting better treatment than previously. Or it could be that, in general, rates of vitamin D deficiency have decreased over time, due to increasing intake of supplements or fortified foods. Either of these factors could obscure potential benefits from taking vitamin D supplements. Regardless of the reason, these most recent findings are likely to be correct for people living with asthma today.
This also highlights why it’s vital to update reviews when more research is published.”
Today’s review includes data from 20 clinical trials, compared with nine in the 2016 review, and children with asthma are better represented than previously. The review team say they have also applied stricter criteria on which studies would be included, compared to some other reviews. For example, they excluded studies that did not compare vitamin D with a placebo and those that did not monitor patients for at least 12 weeks.
Most of the trials included in the review involved patients taking cholecalciferol, which is the typical form of vitamin D supplement. One trial that used calcidiol, which is a compound that the body can make from vitamin D, reported an improvement in asthma control in patients taking this supplement. The reviewers say further research is needed to confirm whether this form of vitamin D has benefits for people with asthma.
- Read the full review on the Cochrane Library
- Read the Evidently Cochrane blog 'Vitamin D for asthma: new evidence, new message'
Williamson A, Martineau AR, Sheikh A, Jolliffe D, Griffiths CJ. Vitamin D for the management of asthma. Cochrane Database of Systematic Reviews 2023, Issue 2. Art. No.: CD011511. DOI: 10.1002/14651858.CD011511.pub3.
Monday, February 6, 2023